People silhouette rendering


Kate Adamczuk, PhD

Senior Scientist

Kate Adamczuk, Ph.D., is a Senior Scientist at Bioclinica. She oversees Molecular Imaging endpoints across phase I to III of multi-center neuroscience clinical trials. Her main goal is to utilize Molecular Imaging in combination with other biomarkers to facilitate the success of neuroscience clinical trials and accelerate patients’ benefits.

With more than ten years of experience in neuroscience and medical imaging, including positron emission tomography (PET), single-photon emission computerized tomography (SPECT), structural and functional magnetic resonance imaging (MRI), she develops clinical trial design strategies, serves as a scientific expert to Bioclinica clients and staff, plans and executes imaging research, and designs and assists with the implementation of processing pipelines. 

Dr. Adamczuk completed her Ph.D. in Biomedical Sciences in the Department of Neurology at the University of Leuven (KU Leuven), where she focused on amyloid PET imaging and its correlation to genetic factors, language networks, cerebrospinal fluid biomarkers, and comparison across amyloid tracers in preclinical Alzheimer’s Disease (AD), Mild Cognitive Impairment and AD patients. During her Post-Doctoral Fellowship in the Department of Neurology at the Harvard Medical School and the Massachusetts General Hospital, she extended her research to Primary Progressive Aphasia and Frontotemporal Dementia patients and added tau and fluorodeoxyglucose (FDG) PET modalities.